ANI Pharmaceuticals posts Q3 revenue of $228 million, up 54%, and raises 2025 guidance
ANI Pharmaceuticals filed an updated investor presentation that restates its third-quarter 2025 results, with total revenue of $228 million, up 54% year over year, and adjusted diluted EPS of $2.04, up 52%. The presentation says the company raised its full-year 2025 guidance for net revenue, adjusted EBITDA and adjusted diluted EPS, with the guidance issued on November 7, 2025. For shareholders, the higher outlook is a positive signal, although ILUVIEN revenue was pressured and the profit figures are non-GAAP measures.
Key points
- Q3 2025 total revenue was $228 million, up 54% year over year; adjusted non-GAAP EBITDA was $60 million, up 70%; adjusted non-GAAP diluted EPS was $2.04, up 52%.
- Full-year 2025 net revenue guidance is $854 million to $873 million, up from a previous $818 million to $843 million.
- Full-year 2025 adjusted non-GAAP EBITDA guidance is $221 million to $228 million (previously $213 million to $223 million), and adjusted non-GAAP diluted EPS guidance is $7.37 to $7.64 (previously $6.98 to $7.35).
- Q3 2025 ILUVIEN revenue was $17 million, which the company said was pressured by reduced access for Medicare patients and remaining YUTIQ units at physician offices.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 10, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.